{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:32:00Z","timestamp":1773315120955,"version":"3.50.1"},"reference-count":30,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031315","name":"AstraZeneca UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2026,2,23]]},"DOI":"10.1136\/ejhpharm-2025-004897","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:20:11Z","timestamp":1773249611000},"page":"ejhpharm-2025-004897","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of a pharmacist-led medication review and optimisation service in the management of cardiometabolic disease"],"prefix":"10.1136","author":[{"given":"Pauline","family":"Coleman","sequence":"first","affiliation":[{"name":"South West Acute Hospital, Enniskillen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Keenan","sequence":"additional","affiliation":[{"name":"South West Acute Hospital, Enniskillen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Monaghan","sequence":"additional","affiliation":[{"name":"South West Acute Hospital, Enniskillen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1500-7593","authenticated-orcid":false,"given":"Rachel","family":"Glass","sequence":"additional","affiliation":[{"name":"Medicines Optimisation Innovation Centre, Antrim, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Gardner","sequence":"additional","affiliation":[{"name":"Medicines Optimisation Innovation Centre, Antrim, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenda F","family":"Fleming","sequence":"additional","affiliation":[{"name":"Medicines Optimisation Innovation Centre, Antrim, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4048-0937","authenticated-orcid":false,"given":"Michael G","family":"Scott","sequence":"additional","affiliation":[{"name":"Medicines Optimisation Innovation Centre, Antrim, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2026031110200640000_ejhpharm-2025-004897v1.1","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.93579"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s11906-003-0085-y","article-title":"Cardiometabolic syndrome: pathophysiology and treatment","volume":"5","author":"Castro","year":"2003","journal-title":"Curr Hypertens Rep"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.3","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-021-02126-x","article-title":"Association between cardiometabolic disease multimorbidity and all-cause mortality in 2 million women and men registered in UK general practices","volume":"19","author":"Canoy","year":"2021","journal-title":"BMC Med"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(14)70219-0"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.5","first-page":"5260","article-title":"Association of cardiometabolic multimorbidity with mortality","volume":"314","year":"2015","journal-title":"JAMA"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.02.012"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.7","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0728-6"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.8","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/s41591-019-0642-9","article-title":"Toward a broader response to cardiometabolic disease","volume":"25","author":"Ralston","year":"2019","journal-title":"Nat Med"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.9","doi-asserted-by":"crossref","DOI":"10.1007\/s11936-017-0522-x","article-title":"Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond","volume":"19","author":"Martens","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01429-5"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.14","article-title":"Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease","volume":"9","author":"Lo","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz486"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.16","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2333"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad195"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.18","unstructured":"National Institute for Health and Care Excellence (NICE) . Type 2 diabetes in adults: management. NICE Guideline NG28. 2022. Available: https:\/\/www.nice.org.uk\/guidance\/ng28"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.19","unstructured":"National Institute for Health and Care Excellence (NICE) . Chronic kidney disease: assessment and management. NICE Guideline NG203. 2021. Available: https:\/\/www.nice.org.uk\/guidance\/ng203"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.20","unstructured":"Department of Health, Social Services and Public Safety (DHSSPS) . Northern Ireland Medicines Optimisation Quality Framework, 2016. Available: https:\/\/www.health-ni.gov.uk\/sites\/default\/files\/consultations\/dhssps\/medicines-optimisation-quality-framework.pdf"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.21","unstructured":"iSIMPATHY Consortium . Summary and Evaluation Report, 2023. Available: https:\/\/www.isimpathy.eu\/summary"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.22","unstructured":"National Institute for Health and Care Excellence (NICE) . Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE Guideline NG238. 2023. Available: https:\/\/www.nice.org.uk\/guidance\/ng238"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90144-C"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.2042-7174.1992.tb00556.x","article-title":"Assessing the quality of ward pharmacists\u2019 interventions","volume":"1","author":"Eadon","year":"2011","journal-title":"Int J Pharm Pract"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.25","doi-asserted-by":"publisher","DOI":"10.1258\/jhsrp.2007.007011"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.26","unstructured":"Campbell F , Karnon J , CzoskiMurray C , et al . University of Sheffield School of Health and Related Research ScHARR; A systematic review of the effectiveness and costeffectiveness of interventions aimed at preventing medication error at hospital admission, 2014. Available: http:\/\/www.eprescribingtoolkit.com\/wp-content\/uploads\/2013\/11\/PatientSafetyMedsSystematicReview.pdf"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.27","unstructured":"NHS England Health and Social Care Information Centre . Hospital outpatient activity 2019-20. NHS Digital; 2020. Available: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/hospital-outpatient-activity\/2019-20\/summary-report---attendances"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.28","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080176"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.29","article-title":"ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure","volume":"136","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026031110200640000_ejhpharm-2025-004897v1.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39609.449676.25"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2025-004897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:20:20Z","timestamp":1773249620000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2025-004897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":30,"alternative-id":["10.1136\/ejhpharm-2025-004897"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2025-004897","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]}}}